Absci (ABSI) stock price is $8.54, up 3.52% on the day, as of Oct 19, 2026. It has a market cap of $1.34Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.34 Bn
P/E-11.11
P/S861.50
Div. Yield0.00
Total Debt (Qtr)150,000.00
Revenue Growth (1y) (Qtr)-46.37
Add ratio to table…
About
Absci Corporation is a clinical-stage biopharmaceutical company specializing in the development of differentiated antibody therapeutics through an AI-native approach. The company combines generative AI models with high-throughput laboratory validation to design and optimize antibody-based drugs targeting underexplored biological mechanisms. Absci’s platform accelerates drug discovery, reducing development timelines and costs compared to traditional methods, while focusing…
Absci Corporation is a clinical-stage biopharmaceutical company specializing in the development of differentiated antibody therapeutics through an AI-native approach. The company combines generative AI models with high-throughput laboratory validation to design and optimize antibody-based drugs targeting underexplored biological mechanisms. Absci’s platform accelerates drug discovery, reducing development timelines and costs compared to traditional methods, while focusing on areas with significant unmet medical needs.
Absci generates revenue through three primary avenues: advancing internally developed drug candidates, partnering or out-licensing select pipeline assets, and collaborating with third parties to leverage its Integrated Drug Creation platform. Internally developed programs, such as ABS-201 for androgenetic alopecia and endometriosis, are designed to address high-unmet-need indications and may eventually yield commercial product sales. Partnerships and out-licensing arrangements provide non-dilutive capital through upfront fees, research funding, clinical and commercial milestones, and royalties. The company also enters drug creation collaborations with pharmaceutical and biotechnology firms, offering its AI-driven platform to support early-stage discovery efforts.
The company operates through the following segments:
Internally Developed Programs: This segment focuses on advancing proprietary drug candidates from AI-driven design through clinical development. Absci prioritizes underexplored biological targets in areas such as dermatology, women’s health, and immunology, where existing therapies are inadequate. The lead candidate, ABS-201, targets the prolactin receptor for androgenetic alopecia and endometriosis, with Phase 1/2a trials underway. Additional preclinical programs address oncology and inflammatory diseases, with select assets earmarked for partnerships or out-licensing.
Partnered Programs: This segment encompasses collaborations with third-party biopharmaceutical companies to apply Absci’s AI-native platform for drug discovery and co-development. Partnerships typically involve upfront payments, research funding, and milestone-based compensation, along with royalties on future product sales. Absci has established partnerships with companies such as Merck, AstraZeneca, and Almirall, leveraging its platform to design novel antibody therapeutics for external pipelines.
Absci occupies a distinctive position within the biopharmaceutical industry by integrating AI with wet-lab validation to create a lab-in-the-loop drug discovery platform. The company’s competitive advantages include its ability to design antibodies against "zero-prior" epitopes—targets lacking pre-existing structural data—using its proprietary Origin-1 model. This capability enables Absci to address difficult-to-drug targets more efficiently than traditional methods, which often rely on lengthy and costly screening processes. Competitors in the AI-driven drug discovery space include Generate Biomedicines and Xaira Therapeutics, while clinical-stage rivals for its lead programs include Hope Medicine and Pelage Pharmaceuticals. Absci’s platform has demonstrated capital efficiency, advancing programs to IND-enabling studies in approximately two years at a cost of $15 million per program, compared to the industry average of 4–6 years and over $50 million.
Absci’s customer base primarily consists of pharmaceutical and biotechnology companies engaged in drug discovery and development partnerships. The company has collaborated with established firms such as Merck, AstraZeneca, and Almirall, providing its AI-driven platform to support their early-stage research. For internally developed programs, Absci’s ultimate customers are patients with conditions such as androgenetic alopecia, endometriosis, and inflammatory bowel disease, where current treatment options are limited or ineffective.
Sectors:Healthcare·TechnologySector rationaleAbsci is primarily a biopharmaceutical company that develops antibody therapeutics and operates clinical trials for drug candidates like ABS-201, placing it firmly in Healthcare. It also operates a substantial second business line by selling access to its AI-driven 'Integrated Drug Creation' platform to other pharmaceutical firms (e.g., Merck, AstraZeneca), which constitutes a technology-as-a-service revenue model.Industries:BiotechnologyBiotechnologyPrimaryAbsci is a clinical-stage biopharmaceutical company that researches and develops antibody-based therapeutics, such as ABS-201, using biological science. Its revenue model includes the development of its own pipeline and receiving milestone payments and royalties from biologic product collaborations.Healthcare ITHealthcare ITSecondaryThe company sells access to its 'Integrated Drug Creation' platform and 'Origin-1' generative AI model to pharmaceutical and biotechnology firms like Merck and AstraZeneca to support their early-stage drug discovery operations.Classified using BQ-MICSCIK: 0001672688
Bull & bear
Investment Thesis
▲ Bull case
The company’s OriginOne platform combined with agentic AI workflows is creating a step change in drug discovery speed and cost efficiency. These tools allow rapid generation of high quality antibodies against challenging targets such as the prolactin receptor. Management highlighted that internal programs are progressing with fewer external CRO expenses and faster timelines. The resulting cost savings extend the cash runway and increase the probability of hitting multiple value inflection points.
ABS201 aims to establish a new therapeutic class in androgenic alopecia by delivering durable hair regrowth from a few injections. The mechanism targets the prolactin receptor offering a regenerative effect that could last years. Market research indicates a total addressable market exceeding 25 billion dollars in the United States alone if the product achieves efficacy comparable to high dose oral minoxidil. The product could also be used alongside existing standard of care expanding the overall market rather than merely replacing it.
Parallel progress in endometriosis and the new ABS202 program expands the prolactin franchise into additional large indications. Endometriosis affects up to 10% of women worldwide representing a significant unmet need for disease modifying therapy. ABS202 is being explored for undisclosed immune and inflammatory indications where prolactin receptor inhibition may offer a novel mechanism. Success in any of these areas would create multiple growth drivers and reduce reliance on a single asset.
The balance sheet shows cash cash equivalents and marketable securities of 125,700,000 dollars at quarter end providing funding into 2028 based on current projections. This liquidity supports upcoming catalysts including initial safety PK data interim 13 week proof of concept readouts and the start of a Phase 2 endometriosis trial. Achieving these milestones would generate valuable data points that could attract partnership interest or enable further internal investment. A strong cash position reduces dilution risk and allows the company to pursue opportunistic business development.
The company’s OriginOne platform combined with agentic AI workflows is creating a step change in drug discovery speed and cost efficiency. These tools allow rapid generation of high quality antibodies against challenging targets such as the prolactin receptor. Management highlighted that internal programs are progressing with fewer external CRO expenses and faster timelines. The resulting cost savings extend the cash runway and increase the probability of hitting multiple value inflection points.
ABS201 aims to establish a new therapeutic class in androgenic alopecia by delivering durable hair regrowth from a few injections. The mechanism targets the prolactin receptor offering a regenerative effect that could last years. Market research indicates a total addressable market exceeding 25 billion dollars in the United States alone if the product achieves efficacy comparable to high dose oral minoxidil. The product could also be used alongside existing standard of care expanding the overall market rather than merely replacing it.
Parallel progress in endometriosis and the new ABS202 program expands the prolactin franchise into additional large indications. Endometriosis affects up to 10% of women worldwide representing a significant unmet need for disease modifying therapy. ABS202 is being explored for undisclosed immune and inflammatory indications where prolactin receptor inhibition may offer a novel mechanism. Success in any of these areas would create multiple growth drivers and reduce reliance on a single asset.
The balance sheet shows cash cash equivalents and marketable securities of 125,700,000 dollars at quarter end providing funding into 2028 based on current projections. This liquidity supports upcoming catalysts including initial safety PK data interim 13 week proof of concept readouts and the start of a Phase 2 endometriosis trial. Achieving these milestones would generate valuable data points that could attract partnership interest or enable further internal investment. A strong cash position reduces dilution risk and allows the company to pursue opportunistic business development.
Clinical success of ABS201 remains unproven and the Phase 1 2a trial is still early with only safety and pharmacokinetic data expected in the near term. The proof of concept readout for hair regrowth is not scheduled until early 2027 leaving a long period of uncertainty for investors. Any failure to demonstrate efficacy comparable to existing therapies would jeopardize the entire pipeline built around this asset. The regenerative mechanism has limited clinical validation in humans increasing the technical risk.
The prolactin biology space is less explored and the link between receptor inhibition and hair growth or endometriosis symptom relief is not fully established. Preclinical data may not translate to human efficacy especially given the complex feedback loops involving prolactin and other hormones. If the mechanism proves insufficient the company may need to abandon or significantly redesign its programs resulting in sunk costs. This biological uncertainty could be exacerbated by variability in patient response due to age genetics or disease subtype.
Endometriosis trials are notoriously plagued by high placebo response which can obscure true drug effect and increase the likelihood of failed readouts. Management acknowledged they will invest heavily in site selection investigator training and blinded data surveillance to mitigate this issue but these efforts add operational complexity and cost. Even with rigorous controls a strong placebo signal could diminish the perceived efficacy of ABS201 in this indication. A negative or inconclusive endometriosis result would weaken the overall franchise narrative.
Cash burn remains elevated with research and development expenses of 19 point 3 million dollars for the quarter and selling general and administrative expenses of 9 point 1 million dollars. While management projects cash sufficient into 2028 this assumes no unexpected setbacks and continued access to financing markets. Any delay in clinical milestones would increase cash consumption and could necessitate dilutive financing or strategic asset sales at unfavorable terms. Dependence on partnering or platform collaborations for non dilutive cash adds another layer of uncertainty if potential partners prioritize internal programs.
Clinical success of ABS201 remains unproven and the Phase 1 2a trial is still early with only safety and pharmacokinetic data expected in the near term. The proof of concept readout for hair regrowth is not scheduled until early 2027 leaving a long period of uncertainty for investors. Any failure to demonstrate efficacy comparable to existing therapies would jeopardize the entire pipeline built around this asset. The regenerative mechanism has limited clinical validation in humans increasing the technical risk.
The prolactin biology space is less explored and the link between receptor inhibition and hair growth or endometriosis symptom relief is not fully established. Preclinical data may not translate to human efficacy especially given the complex feedback loops involving prolactin and other hormones. If the mechanism proves insufficient the company may need to abandon or significantly redesign its programs resulting in sunk costs. This biological uncertainty could be exacerbated by variability in patient response due to age genetics or disease subtype.
Endometriosis trials are notoriously plagued by high placebo response which can obscure true drug effect and increase the likelihood of failed readouts. Management acknowledged they will invest heavily in site selection investigator training and blinded data surveillance to mitigate this issue but these efforts add operational complexity and cost. Even with rigorous controls a strong placebo signal could diminish the perceived efficacy of ABS201 in this indication. A negative or inconclusive endometriosis result would weaken the overall franchise narrative.
Cash burn remains elevated with research and development expenses of 19 point 3 million dollars for the quarter and selling general and administrative expenses of 9 point 1 million dollars. While management projects cash sufficient into 2028 this assumes no unexpected setbacks and continued access to financing markets. Any delay in clinical milestones would increase cash consumption and could necessitate dilutive financing or strategic asset sales at unfavorable terms. Dependence on partnering or platform collaborations for non dilutive cash adds another layer of uncertainty if potential partners prioritize internal programs.